Jarosz Alicja, Szyluk Karol, Iwanicka Joanna, Balcerzyk Anna, Nowak Tomasz, Iwanicki Tomasz, Negru Marius, Kalita Marcin, Francuz Tomasz, Garczorz Wojciech, Górczyńska-Kosiorz Sylwia, Kania Wojciech, Niemiec Paweł
Department of Biochemistry and Medical Genetics, School of Health Sciences in Katowice, Medical University of Silesia in Katowice, Medyków 18 St., 40-752 Katowice, Poland.
District Hospital of Orthopaedics and Trauma Surgery, Bytomska 62 St., 41-940 Piekary Śląskie, Poland.
J Clin Med. 2022 Jun 17;11(12):3504. doi: 10.3390/jcm11123504.
This study aims to identify genotype variants of the platelet-derived growth factor alpha polypeptide gene () that can influence the individual response to the treatment with platelet-rich plasma (PRP) in tennis elbow patients.
We observed a cohort of 107 patients (132 elbows) with tennis elbow who received treatment with PRP. Patients have been followed-up for two years after PRP injection and the effectiveness of the treatment was measured using universal patient-reported outcome measures (PROMs): visual analog scale (VAS), quick version of disabilities of the arm, shoulder and hand score (QDASH), and patient-rated tennis elbow evaluation (PRTEE). PROMs values, and clinical and platelet parameters were compared between genotype variants of the studied polymorphisms (rs1800814, rs2070958 and rs62433334).
The A allele carriers (rs1800814) had significantly lower values of VAS (week 12), QDASH, and PRTEE (weeks 8, 12). The T allele carriers (rs2070958) had significantly lower values of VAS (weeks 8, 12), QDASH, and PRTEE (weeks 4-12). Additional forms of therapy (manual and physical) were necessary significantly more often in GG (rs1800814) and CC (rs2070958) homozygotes.
The gene's polymorphisms influences the effectiveness of PRP therapy in tennis elbow treatment. The effectiveness of PRP is greater in A allele (rs1800814) and T allele (rs2070958) carriers.
本研究旨在确定血小板衍生生长因子α多肽基因（）的基因型变体，这些变体可能影响网球肘患者对富血小板血浆（PRP）治疗的个体反应。
我们观察了一组107例（132个肘部）接受PRP治疗的网球肘患者。在PRP注射后对患者进行了两年的随访，并使用通用的患者报告结局指标（PROMs）来衡量治疗效果：视觉模拟量表（VAS）、手臂、肩部和手部残疾快速评分（QDASH）以及患者自评网球肘评估（PRTEE）。比较了所研究多态性（rs1800814、rs2070958和rs62433334）的基因型变体之间的PROMs值、临床和血小板参数。
A等位基因携带者（rs1800814）的VAS值（第12周）、QDASH值和PRTEE值（第8周、第12周）显著较低。T等位基因携带者（rs2070958）的VAS值（第8周、第12周）、QDASH值和PRTEE值（第4 - 12周）显著较低。在GG（rs1800814）和CC（rs2070958）纯合子中，显著更常需要额外的治疗形式（手法和物理治疗）。
该基因的多态性影响PRP疗法在网球肘治疗中的有效性。在A等位基因（rs1800814）和T等位基因（rs2070958）携带者中，PRP的有效性更高。
